TET vs. VCT, SCPA, ESNT, ZTF, SYNT, IOF, HAYD, WCH, ITX, and DCTA
Should you be buying Treatt stock or one of its competitors? The main competitors of Treatt include Victrex (VCT), Scapa Group (SCPA), Essentra (ESNT), Zotefoams (ZTF), Synthomer (SYNT), Iofina (IOF), Haydale Graphene Industries (HAYD), Wilmcote Holdings plc (WCH.L) (WCH), Itaconix (ITX), and Directa Plus (DCTA). These companies are all part of the "specialty chemicals" industry.
Treatt vs. Its Competitors
Victrex (LON:VCT) and Treatt (LON:TET) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.
In the previous week, Victrex had 1 more articles in the media than Treatt. MarketBeat recorded 1 mentions for Victrex and 0 mentions for Treatt. Treatt's average media sentiment score of 0.00 beat Victrex's score of -0.13 indicating that Treatt is being referred to more favorably in the news media.
75.5% of Victrex shares are held by institutional investors. Comparatively, 42.1% of Treatt shares are held by institutional investors. 4.1% of Victrex shares are held by company insiders. Comparatively, 4.1% of Treatt shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Victrex pays an annual dividend of GBX 0.60 per share and has a dividend yield of 0.1%. Treatt pays an annual dividend of GBX 0.08 per share and has a dividend yield of 0.0%. Victrex pays out 1.8% of its earnings in the form of a dividend. Treatt pays out 0.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Victrex has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Treatt has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
Victrex has a net margin of 10.81% compared to Treatt's net margin of 7.88%. Treatt's return on equity of 8.09% beat Victrex's return on equity.
Victrex currently has a consensus target price of GBX 822, indicating a potential upside of 27.84%. Treatt has a consensus target price of GBX 266.67, indicating a potential upside of 1.98%. Given Victrex's higher probable upside, equities analysts plainly believe Victrex is more favorable than Treatt.
Victrex has higher revenue and earnings than Treatt. Treatt is trading at a lower price-to-earnings ratio than Victrex, indicating that it is currently the more affordable of the two stocks.
Summary
Victrex beats Treatt on 11 of the 18 factors compared between the two stocks.
Get Treatt News Delivered to You Automatically
Sign up to receive the latest news and ratings for TET and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TET and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (LON:TET) was last updated on 10/20/2025 by MarketBeat.com Staff
